Hematology Market: Size, Share, Key Developments, Innovations, and Opportunities Through 2031
Hematology Market Overview
The global hematology
market is projected to grow at a CAGR of approximately 3–5%
through 2027. Demand is propelled by the rapid uptake of
artificial-intelligence enabled automation, the growing burden of hematologic
cancers and anemia, and wider availability of point-of-care (POC) testing
platforms. Automated platforms boost laboratory throughput and cut human-error
rates, while cloud-connected middleware helps laboratories offset skilled-labor
shortages. At the same time, high-parameter flow cytometers improve measurable
residual-disease detection, sustaining premium analyzer sales despite
capital-intensity concerns. Supply-chain risks around porcine-sourced heparin
and data-privacy regulations for connected instruments temper near-term
momentum but are unlikely to derail the broader growth trajectory. North
America retains volume leadership, yet Asia-Pacific is accelerating on the back
of health-infrastructure upgrades and local production investments.
Download Sample Copy: https://meditechinsights.com/global-hematology-market/request-sample/
Hematology is a medical specialty focused on the study
of blood, blood-forming organs, and related disorders. It encompasses a wide
range of benign and malignant conditions affecting red blood cells, white blood
cells, platelets, and the coagulation system in both adults and children.
Hematology specialists are involved in the research, diagnosis, and treatment
of conditions such as anemia, hemophilia and other bleeding disorders, blood
clots, sickle cell disease, and hematological malignancies including leukemia,
lymphoma, and myeloma.
Hematology
Market Trends and Insights
Growth
in AI-enabled Automated CBC Platforms
Low-cost
AI flow-cytometry prototypes developed at Rice University demonstrate
performance comparable to high-end systems, lowering entry barriers for
resource-constrained facilities. The FDA’s reclassification of automated
hemoglobin systems to Class II further eases U.S. market access[1].
Machine-learning algorithms now deliver sub-second cell-morphology recognition,
shrinking turnaround times and supporting adoption in high-volume hospitals.
Cloud analytics also help labs benchmark quality metrics across networks,
reinforcing procurement arguments. Collectively, these gains elevate analyzer
utilization rates and underpin recurring reagent revenues, keeping the
hematology market on a firm growth path.
Rising
Incidence of Hematologic Cancers & Anemia
The
Leukemia & Lymphoma Society counts 1.70 million U.S. residents living with
blood cancers, with 187,740 new cases expected in 2024[2]. Ageing populations
in developed economies drive prevalence, while improved survival extends
monitoring cycles that rely on routine CBC and flow-cytometry panels. Progress
in targeted therapies widens patient eligibility, lifting test volumes.
Advanced economies shoulder the largest caseloads, yet emerging markets are
catching up as diagnostic infrastructure expands. The sustained clinical burden
translates into predictable demand, anchoring the hematology market against
economic volatility.
Expansion
of Decentralized POC Hematology Testing
The
FDA cleared the first POC hepatitis C RNA assay in 2024, signaling regulatory
support for near-patient diagnostics. Portable Hb devices such as Masimo’s SpHb
monitor enable real-time hemoglobin tracking without venipuncture. CMS amended
rules for rural clinics, removing obligatory hemoglobin tests from central-lab
panels and freeing providers to adopt POC workflows. Tele-health integration
allows remote specialists to review results instantaneously, shrinking
treatment delays. These structural shifts move a share of volumes away from
hospital cores into outpatient and community settings, broadening the
hematology market footprint.
Download Sample Copy: https://meditechinsights.com/global-hematology-market/request-sample/
Surge
in Complex Therapies Needing Advanced Blood Monitoring
CAR-T
protocols and gene therapies demand 19-color flow panels for residual-disease
tracking, pushing laboratories toward higher-parameter cytometers. The FDA
approval of Duvyzat for Duchenne muscular dystrophy mandates platelet
monitoring, reinforcing comprehensive hematology panels during therapy. Beckman
Coulter’s DxFLEX clearance underscores industry responsiveness, bringing
13-color immunophenotyping into routine clinical use. As biopharma pipelines
swell with precision treatments, real-time hematologic monitoring becomes
integral, stimulating premium-segment growth within the hematology market.
Impact
of COVID-19 on the Global Hematology Market
The COVID-19 pandemic had a positive impact on the
hematology market, as hematological parameters became critical for assessing
and managing COVID-19 patients worldwide. Demand for hematology analyzers
increased significantly, as these systems were widely used for tests such as
complete blood counts, blood level measurements, and detailed blood sample
analyses.
Since the lungs were the primary organs affected by
COVID-19, hematology testing played an essential role in monitoring red blood
cell (RBC) counts and oxygen transport. Damage to the alveoli disrupted gas
exchange, impairing the ability of red blood cells to carry oxygen. As a
result, hematology tests became vital for evaluating disease severity and
patient outcomes during the pandemic.
Technological
Advancements Driving Market Growth
Ongoing technological innovation remains a major force
propelling the global hematology market. Manufacturers continue to introduce
advanced analyzers that improve workflow efficiency, accuracy, and throughput
in laboratories.
For example, in May 2023, Siemens Healthineers launched
the next-generation Atellica HEMA 570 and Atellica HEMA 580 analyzers, designed
for high-volume testing with intuitive user interfaces and enhanced automation
connectivity. Similarly, in July 2022, HORIBA Medical expanded its Yumizen H500
and H550 product family with compact benchtop analyzers offering improved
performance, new functionalities, and added value for laboratories.
As highlighted by a director at a leading U.S.-based
hematology analyzer manufacturer, the increasing incidence of blood disorders,
rapid technological advancements, and the ongoing digital transformation of
hematology laboratories are key growth drivers. In the European Union alone, an
estimated 80 million people are affected by blood disorders.
AI-Powered
Hematology Analyzers Enhancing Diagnostic Capabilities
Traditional hematology analyzers often provide limited
diagnostic insights, while the growing volume of laboratory data can overwhelm
clinicians. AI-powered automatic hematology analyzers address this challenge by
applying artificial intelligence to convert complex data into clinically
meaningful insights. These systems help reduce turnaround times, minimize
misclassifications, and lower the workload for healthcare professionals.
An example is the DH-615 hematology analyzer from
Dymind Biotechnology, which combines fluorescent nucleic acid staining with the
company’s proprietary AI Cube technology. By integrating 6-DIFF with
reticulocyte (RET) analysis, the system significantly improves abnormal cell
detection and enhances the assessment of hematological diseases.
Browse Report: https://meditechinsights.com/global-hematology-market/
Competitive
Landscape of the Hematology Market
The global hematology market is highly competitive,
with the presence of several established players, including:
- Sysmex Corporation
- Beckman Coulter (Danaher Corporation)
- Siemens Healthineers
- Abbott
- Mindray
- Nihon Kohden
- Boule Diagnostics
- Bio-Rad Laboratories
- HORIBA
- Drew Scientific
Growth
Strategies Adopted by Market Leaders
Leading companies in the hematology market employ a
combination of organic and inorganic growth strategies, such as new product
launches, partnerships, and collaborations, to strengthen their market
position.
For instance, in July 2022, Beckman Coulter partnered
with Scopio Labs to accelerate the adoption of digital cell morphology
platforms in hematology. In March 2022, Mindray introduced the BC-700 Series, a
compact and integrated CBC and ESR hematology analyzer designed for small- to
mid-sized laboratories.
Related Report:
Pain Management Devices Market https://www.pharmiweb.com/press-release/2026-05-12/pain-management-devices-market-emerging-as-a-high-growth-healthcare-investment-space-through-2030
Anti-snoring Devices Market https://www.pharmiweb.com/press-release/2026-05-12/anti-snoring-devices-market-revenue-modeling-and-strategic-forecast-2026-to-2031
Hospital Information Systems Market https://www.pharmiweb.com/press-release/2026-05-14/hospital-information-systems-market-size-is-expected-to-witness-substantial-growth-at-a-significant-cagr-by-2031
Bunion Surgery Market https://www.pharmiweb.com/press-release/2026-05-14/bunion-surgery-market-growth-outlook-segmentation-industry-trends-2026-2031
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment